<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30242135</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1091-6490</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>115</Volume>                    <Issue>41</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>10</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>            </Journal>            <ArticleTitle>Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment.</ArticleTitle>            <Pagination>                <MedlinePgn>E9640-E9648</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1809695115</ELocationID>            <Abstract>                <AbstractText>Breast cancer stem cells (BCSCs), which are characterized by a capacity for unlimited self-renewal and for generation of the bulk cancer cell population, play a critical role in cancer relapse and metastasis. Hypoxia is a common feature of the cancer microenvironment that stimulates the specification and maintenance of BCSCs. In this study, we found that hypoxia increased expression of adenosine receptor 2B (A2BR) in human breast cancer cells through the transcriptional activity of hypoxia-inducible factor 1. The binding of adenosine to A2BR promoted BCSC enrichment by activating protein kinase C-Î´, which phosphorylated and activated the transcription factor STAT3, leading to increased expression of interleukin 6 and NANOG, two key mediators of the BCSC phenotype. Genetic or pharmacological inhibition of A2BR expression or activity decreased hypoxia- or adenosine-induced BCSC enrichment in vitro, and dramatically impaired tumor initiation and lung metastasis after implantation of MDA-MB-231 human breast cancer cells into the mammary fat pad of immunodeficient mice. These data provide evidence that targeting A2BR might be an effective strategy to eradicate BCSCs.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lan</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Haiquan</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Samanta</LastName>                    <ForeName>Debangshu</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Salman</LastName>                    <ForeName>Shaima</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>You</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Semenza</LastName>                    <ForeName>Gregg L</ForeName>                    <Initials>GL</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205; gsemenza@jhmi.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>21</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>            <NlmUniqueID>7505876</NlmUniqueID>            <ISSNLinking>0027-8424</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D051793">Hypoxia-Inducible Factor 1</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D043704">Receptor, Adenosine A2B</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.13</RegistryNumber>                <NameOfSubstance UI="C497258">PRKCD protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.13</RegistryNumber>                <NameOfSubstance UI="D051745">Protein Kinase C-delta</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>FASEB J. 2006 Nov;20(13):2242-50</RefSource>                <PMID Version="1">17077301</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7</RefSource>                <PMID Version="1">16916931</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 1996 Dec 20;271(51):32529-37</RefSource>                <PMID Version="1">8955077</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Jul 1;65(13):5506-11</RefSource>                <PMID Version="1">15994920</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2012 Apr 5;31(14):1757-70</RefSource>                <PMID Version="1">21860410</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Pharmacol. 2006 Aug;70(2):727-35</RefSource>                <PMID Version="1">16707627</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Immunol Immunother. 2011 Oct;60(10):1405-18</RefSource>                <PMID Version="1">21638125</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2012 Feb 3;148(3):399-408</RefSource>                <PMID Version="1">22304911</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer. 2017 Jun 7;16(1):99</RefSource>                <PMID Version="1">28592285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>In Vitro Cell Dev Biol Anim. 2017 Feb;53(2):132-140</RefSource>                <PMID Version="1">27670764</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Mar 10;27(8):1160-7</RefSource>                <PMID Version="1">19204204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Purinergic Signal. 2013 Jun;9(2):271-80</RefSource>                <PMID Version="1">23315335</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Pharmacol. 2011;61:41-75</RefSource>                <PMID Version="1">21586355</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Signal. 2003 Sep;15(9):813-27</RefSource>                <PMID Version="1">12834807</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23</RefSource>                <PMID Version="1">26512116</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuron. 2017 Dec 6;96(5):1070-1083.e5</RefSource>                <PMID Version="1">29154125</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2017 Apr 6;36(14):2023-2029</RefSource>                <PMID Version="1">27694896</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2017 Jan;67(1):7-30</RefSource>                <PMID Version="1">28055103</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Purinergic Signal. 2009 Sep;5(3):289-98</RefSource>                <PMID Version="1">19125355</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Sci. 2006 Feb 1;119(Pt 3):470-81</RefSource>                <PMID Version="1">16418226</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2784-9</RefSource>                <PMID Version="1">22308314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44</RefSource>                <PMID Version="1">23483055</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Dev. 2003 May 15;17(10):1253-70</RefSource>                <PMID Version="1">12756227</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4600-9</RefSource>                <PMID Version="1">26229077</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Crit Rev Biochem Mol Biol. 2014 Nov-Dec;49(6):473-97</RefSource>                <PMID Version="1">25418535</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochimie. 2015 Aug;115:59-70</RefSource>                <PMID Version="1">25956975</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Immunol. 2017 Dec;17(12):774-785</RefSource>                <PMID Version="1">28972206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Stem Cell. 2007 Nov;1(5):555-67</RefSource>                <PMID Version="1">18371393</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Differ. 2007 Jul;14(7):1315-23</RefSource>                <PMID Version="1">17396131</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circ Res. 2002 Mar 22;90(5):531-8</RefSource>                <PMID Version="1">11909816</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Pathol. 2010 Nov;41(11):1550-7</RefSource>                <PMID Version="1">20619442</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neoplasia. 2017 Jul;19(7):530-536</RefSource>                <PMID Version="1">28582704</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248</RefSource>                <PMID Version="1">29367423</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta. 2016 Mar;1863(3):382-391</RefSource>                <PMID Version="1">26079100</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 2011 Dec 1;187(11):6120-9</RefSource>                <PMID Version="1">22039302</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 2015 Nov 1;98(1):110-8</RefSource>                <PMID Version="1">26296573</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2047-56</RefSource>                <PMID Version="1">27001847</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2014 Dec 30;5(24):12509-27</RefSource>                <PMID Version="1">25587023</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2003 Jul 18;307(1):180-7</RefSource>                <PMID Version="1">12849998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Med (Berl). 2013 Feb;91(2):183-93</RefSource>                <PMID Version="1">23263788</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2011 May;32(5):650-8</RefSource>                <PMID Version="1">21310941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Breast Cancer. 2015 Dec;18(4):303-12</RefSource>                <PMID Version="1">26770236</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Immunol. 2012 Jan 1;188(1):198-205</RefSource>                <PMID Version="1">22116822</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Stem Cell. 2014 Mar 6;14(3):306-21</RefSource>                <PMID Version="1">24607405</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Signal. 2013 May 28;6(277):ra39</RefSource>                <PMID Version="1">23716716</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JACC Cardiovasc Interv. 2014 Jun;7(6):581-91</RefSource>                <PMID Version="1">24835328</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Oct 4;7(40):64527-64542</RefSource>                <PMID Version="1">27590511</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2011 Jun;11(6):393-410</RefSource>                <PMID Version="1">21606941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource>                <PMID Version="1">23000897</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38</RefSource>                <PMID Version="1">25453096</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52</RefSource>                <PMID Version="1">20080644</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5</RefSource>                <PMID Version="1">19805192</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Pharmacol. 2018 Jan 31;9:54</RefSource>                <PMID Version="1">29445342</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Immunol. 2016 Mar 29;7:109</RefSource>                <PMID Version="1">27066002</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8</RefSource>                <PMID Version="1">12629218</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2016 Aug 1;76(15):4372-82</RefSource>                <PMID Version="1">27221704</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2001 Apr;107(7):861-9</RefSource>                <PMID Version="1">11285305</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacol Rev. 1994 Jun;46(2):143-56</RefSource>                <PMID Version="1">7938164</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Heart J. 2014 Oct 1;35(37):2516-23</RefSource>                <PMID Version="1">24796339</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Cancer. 2016 Jun;2(6):295-304</RefSource>                <PMID Version="1">28741527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2008 Feb 19;117(7):886-96</RefSource>                <PMID Version="1">18250271</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Med (Berl). 2013 Feb;91(2):147-55</RefSource>                <PMID Version="1">23334369</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Pharmacol Sci. 2016 Jun;37(6):419-434</RefSource>                <PMID Version="1">26944097</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86</RefSource>                <PMID Version="1">19020076</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pharmacol Exp Ther. 2016 Apr;357(1):36-44</RefSource>                <PMID Version="1">26791603</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051793" MajorTopicYN="N">Hypoxia-Inducible Factor 1</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051745" MajorTopicYN="N">Protein Kinase C-delta</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D043704" MajorTopicYN="N">Receptor, Adenosine A2B</DescriptorName>                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">ADORA2B</Keyword>            <Keyword MajorTopicYN="Y">HIF-1</Keyword>            <Keyword MajorTopicYN="Y">caffeine</Keyword>            <Keyword MajorTopicYN="Y">oxygen</Keyword>            <Keyword MajorTopicYN="Y">tumor-initiating cells</Keyword>        </KeywordList>        <CoiStatement>The authors declare no conflict of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pmc-release">                <Year>2019</Year>                <Month>04</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30242135</ArticleId>            <ArticleId IdType="pii">1809695115</ArticleId>            <ArticleId IdType="doi">10.1073/pnas.1809695115</ArticleId>            <ArticleId IdType="pmc">PMC6187157</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>